welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Cancer Prevention Pharmaceuticals, Inc. (“CPP”) announced today the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to evaluate CPP-1X in patients with precancerous gastric lesions who are at high risk for gastric cancer.
The trial is funded by the National Cancer Institute (NCI) and run in collaboration with Keith T. Wilson, M.D., and Douglas R. Morgan, M.D., MPH, of Vanderbilt University School of Medicine, Vanderbilt University Medical Center, and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
- Endoscopic Submucosal Dissection to Treat Ileal High-Grade Dysplasia After Ileoanal Anastomosis for Familial Adenoma...Restorative proctocolectomy has become t...
- Proctocolectomy for Ulcerative Colitis or Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=zlxBwxKX...
- Screening and Surveillance of the Early Detection of Colorectal Cancer and Adenomatous PolypsIn the United States, colorectal cancer ...
- Thetis Pharmaceuticals Awarded Key Patent on HEALER TechnologyThetis Pharmaceuticals LLC, a privately-...
- Iron infusionshttps://www.youtube.com/watch?v=OaFSmO4p...
- Surgical Treatment of Familial Adenomatous Polyposis: Dilemmas and Current RecommendationsFamilial adenomatous polyposis (FAP) is ...
- Familial Adenomatous Polyposis: Ileo-Anal Pouch versus Ileo-Rectal AnastomosisAIM : In this study we describe the pres...
English
Portuguese
Spanish